MindMed Appoints Brandi Roberts as Chief Financial Officer

LOS ANGELES- Mind Medicine  has announced the appointment of Brandi L. Roberts, CPA, as its Chief Financial Officer, effective June 2, 2025. Roberts will oversee the company’s financial strategy, capital planning, accounting, investor relations, and information technology as MindMed advances its clinical development and commercial initiatives for its lead product candidate, MM120, an orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Roberts brings over 25 years of financial leadership experience in the life sciences industry. Most recently, she served as CFO and Executive Vice President at Longboard Pharmaceuticals, where she played a pivotal role in the company’s initial public offering, multiple financings, and its $2.6 billion acquisition by Lundbeck in 2024. Her previous roles include CFO positions at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, as well as senior finance roles at Alphatec Spine, Artes Medical, Stratagene Corporation, and Pfizer.

In connection with her appointment, MindMed will grant Roberts an option to purchase 500,000 common shares and 125,000 performance share units (PSUs), subject to performance metrics and continued employment. The option will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent three years. The PSUs will vest on the third anniversary of the grant date, contingent upon the achievement of specified performance goals.

As of May 29, 2025, MindMed’s stock is trading at $7.29, reflecting a year-to-date return of 4.89%. The company maintains a strong balance sheet with cash reserves of $245.5 million, providing financial flexibility as it continues to invest in its Phase 3 trials for MM120 ODT. MindMed has also amended a loan agreement to access up to $120 million, enhancing its financial position.

Roberts’ appointment comes as MindMed progresses its clinical programs, with top-line data from its Phase 3 trials for MM120 ODT expected in 2026. The company has received Breakthrough Therapy Designation for MM120 ODT in GAD, indicating potential regulatory advantages. Analyst feedback from firms like RBC Capital Markets suggests ongoing confidence in MindMed’s strategic direction and clinical progress.